Table 1.

Criteria defining quality and duration of response to fulvestrant

QUALITY OF CLINICAL RESPONSE

Patients were assessed clinically every 6 weeks for the first 6 months using bi‐dimensional calliper measurements of their tumour and then at 12 weekly intervals (as per UICC criteria): CR = Complete response to fulvestrant PR = Partial response to fulvestrant SD = Stable disease on fulvestrant CB = clinical benefit on fulvestrant, i.e., Complete or Partial response or Stable disease for >= 6 months PD = progressive disease, i.e., progression of disease on fulvestrant within 6 months

CLINICAL RESPONSE DURATION

Median DoR = median duration of response between fulvestrant treatment commencement and disease progression on this agent for All‐patients Median DoCB= median duration of response to fulvestrant in patients with CB CB patients were also subdivided into EP (early progressors, i.e., CB tumours progressing prior to median DoCB on fulvestrant) or CONR/LP sub‐sets (continuing responders/late progressors, i.e., CB tumours with fulvestrant responses exceeding median DoCB, including those progressing on fulvestrant after this time). Two CB patients with follow‐up <median DoCB were excluded from EP versus CONR/LP analyses.